Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Allergan Inc patents (2015 archive)


Recent patent applications related to Allergan Inc. Allergan Inc is listed as an Agent/Assignee. Note: Allergan Inc may have other listings under different names/spellings. We're not affiliated with Allergan Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Allergan Inc-related inventors


12/31/15 / #20150376125

Tromethamine salt of bimatoprost acid in crystalline form 1, methods for preparation, and methods for use thereof

The present invention provides tromethamine salt of (z)-7-[3,5-dihydroxy-2-((e)-3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-hept-5-enoic acid in crystalline form 1 and amorphous form. This compound is may also be referred to as “tromethamine salt of bimatoprost acid.” the invention crystalline form is useful for solid ocular implant or topical formulations, utilized in the treatment of various ocular conditions, such as, for example, ocular hypertension.. ... Allergan Inc

12/31/15 / #20150374916

Laterally connected syringes with integrated mixing hub and static mixer

Described herein are laterally connected syringes with an integrated mixing hub and static mixer designed to facilitate mixing two or more substances at specific user-selectable ratios.. . ... Allergan Inc

12/31/15 / #20150374645

Devices and methods for sustained treatment of bladder pain and irritative voiding

Devices and methods are provided for treating a patient having bladder pain and/or irritative voiding symptoms. The method includes administering to the patient's bladder lidocaine or another anesthetic agent continuously over a treatment period of 24 hours or more in an amount effective to achieve a therapeutic effect which is sustained beyond the end of the treatment period.. ... Allergan Inc

12/24/15 / #20150366800

Androgen composition for treating an opthalmic condition

The disclosure provides compositions for treating an ocular condition. The composition comprises a physiologically effective amount of an androgen, wherein the composition is suitable for topical administration to an eye. ... Allergan Inc

12/24/15 / #20150366799

Method of treating allergic conjunctivitis with cyclosporin compositions

Disclosed herein is a method of treating allergic conjunctivitis, the method comprising the step of topically administering to an eye affected with such a condition a composition comprising cyclosporin, at a concentration between about 0.001% (w/v) to about 0.01% (w/v).. . ... Allergan Inc

12/17/15 / #20150359781

Stabilized oxymetazoline formulations and their uses

The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.. ... Allergan Inc

12/10/15 / #20150352251

Dermal filler compositions including antioxidants

Provided are injectable, hyaluronic acid-based hydrogel compositions including conjugated vitamins.. . ... Allergan Inc

12/10/15 / #20150352226

Sustained release poloxamer containing pharmaceutical compositions

A thermo-reversible thermoplastic pharmaceutical composition, comprising a botulinum toxin and a biocompatible poloxamer which provides thermoreversibility to the composition and additionally stabilizes the botulinum toxin, is described. The pharmaceutical composition can be administered to a patient as a liquid, and gels after administration into a sustained release drug delivery system from which the biologically active botulinum toxin is released over a multi-day period thereby localizing the drug as a depot and controlling release to enhance the therapeutic effect per dose.. ... Allergan Inc

12/10/15 / #20150351899

Silk medical device for use in breast augmentation and breast reconstruction

A three-dimensional fabric structure in a form of a pocket for use in a breast reconstruction surgical procedure such as single-stage or two-stage breast reconstruction. The silk scaffold employs a knit pattern that substantially prevents unraveling and preserves the stability of the mesh or scaffold device, especially when the mesh or scaffold device is cut. ... Allergan Inc

12/03/15 / #20150343147

Injection device

Disclosed herein are devices and methods that can provide assistance with extruding and/or aspirating high viscosity materials such as dermal fillers.. . ... Allergan Inc

12/03/15 / #20150343036

Methods for reducing the occurrence or preventing formation of bladder calculi

Methods for reducing the occurrence or preventing formation of bladder calculi associated with bladder augmentation or bladder reconstruction.. . ... Allergan Inc

12/03/15 / #20150343017

Cyclosporin compositions

A composition is disclosed herein comprising from about 0.001% to about 0.4% cyclosporin a, castor oil, and a surfactant selected from the group consisting of alcohol ethoxylates, alcohols, alkyl glycosides, alkyl polyglycosides, alkylphenol ethoxylates, amine oxides, block polymers, carboxylated alcohol or alkylphenol ethoxylates, carboxylic acids/fatty acids, cellulose derivatives, ethoxylated alcohols, ethoxylated alkylphenols, ethoxylated aryl phenols, ethoxylated fatty acids, ethoxylated fatty acids, ethoxylated fatty esters and oils, fatty alcohols, fatty esters, glycol esters, lanolin-based derivatives, lecithin and lecithin derivatives, lignin and lignin derivatives, methyl esters, monoglycerides and derivatives, phosphalipids, polyacrylic acids, polyethylene glycols, polyethylene oxide-polypropylene oxide copolymers, polyethylene oxides, polymeric surfactants, polypropylene oxides, propoxylated alcohols, propoxylated alkyl phenols, propoxylated fatty acids, protein-based surfactants, sarcosine derivatives, silicone-based surfactants, sorbitan derivatives, stearates, sucrose and glucose esters and derivatives, and combinations thereof.. . ... Allergan Inc

11/26/15 / #20150336924

Amidoalkylenyl and amidoaryl esters, compositions thereof, and methods for their use

. . The invention provides ester compounds for treating ophthalmic diseases. The esters of the invention are particularly advantageous due to their stability in aqueous solutions.. ... Allergan Inc

11/19/15 / #20150329518

Therapeutic prostaglandin receptor agonists

. . Described herein are compounds which can be used in topical liquids, creams, or other dosage forms such as solids, for reducing intraocular pressure, treating glaucoma, growing hair, treating wounds, or other medical and/or cosmetic uses.. . ... Allergan Inc

11/19/15 / #20150328405

High force injection devices

Described herein are assisted syringes. The syringes provide a higher force to the plunger tip than the extrusion force applied to the plunger. ... Allergan Inc

11/19/15 / #20150328221

Compounds for protection of photoreceptor cells and for enhancing visual function under low light conditions

Described herein are methods of enhancing visual function under low light conditions and to methods of protecting photoreceptors cells by administration of a compound selected from the group consisting of zalospirone and eptapirone; or a pharmaceutically acceptable salt thereof.. . ... Allergan Inc

11/19/15 / #20150327987

Soft filled prosthesis shell with variable texture

A soft prosthetic implant, such as a silicone breast implant, is provided. The implant has a variety of different surfaces, for example, different textures, located on different areas of the outer surface of the implant.. ... Allergan Inc

11/19/15 / #20150327986

Textured breast implant and methods of making same

Methods for texturing surgical implants, for example, breast implants, are provided. The methods include the use of computer controlled 3d printing of a sacrificial material to create a textured surface on an unfinished surface of the implant.. ... Allergan Inc

11/19/15 / #20150327972

Soft tissue augmentation threads and methods of use thereof

This disclosure relates generally to soft tissue augmentation threads, methods of making such threads and uses thereof, for example, in aesthetic applications (e.g., facial contouring, soft tissue augmentation products), surgery (e.g., sutures), drug delivery, negative pressure wound therapy, moist wound dressing, and the like.. . ... Allergan Inc

11/12/15 / #20150324976

Method for quantifying collagen fiber alignment in periprosthetic tissue

. . A method for quantifying collagen fiber alignment in periprosthetic tissue in a mammal.. . ... Allergan Inc

11/12/15 / #20150322036

Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes

Compositions and methods for treating glaucoma are provided. In particular hydrophilic ester prodrugs and their use to reduce central corneal thickening is provided.. ... Allergan Inc

11/12/15 / #20150320732

Retinoid topical compositions and methods for treating skin conditions

A topical pharmaceutical composition comprising tazarotene and one or more of an anti-inflammatory or anti-bacterial agent. Also provided is a method for treating skin conditions, such as acne utilizing the above topical pharmaceutical composition.. ... Allergan Inc

11/05/15 / #20150314040

Stable hydrogel compositions including additives

The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions.. . ... Allergan Inc

11/05/15 / #20150313974

Methods for treating headache

A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type a and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache.. ... Allergan Inc

11/05/15 / #20150313973

Formulations of biologics for intravesical instillation

Pharmaceutical formulations comprising a clostridial derivative and a permeabilizing agent for intravesical instillation are disclosed.. . ... Allergan Inc

10/29/15 / #20150306280

Stable hydrogel compositions including additives

The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions.. . ... Allergan Inc

10/29/15 / #20150305854

Variable surface breast implant

A variable textured breast implant is provided including a front surface that has a porous texture and a back surface having a smooth or less porous texture than the front surface texture.. . ... Allergan Inc

10/29/15 / #20150305853

Lighter weight implant

A breast implant is provided which includes a filling, or core having a lower overall density relative to silicone gel-filled or saline-filled implant. The core may be a composite including flexible, bodies, for example, air-containing, or gas-containing, bodies, and a gel medium between or around the bodies.. ... Allergan Inc

10/22/15 / #20150301050

Immuno-based retargeted endopeptidase activity assays

The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.. . ... Allergan Inc

10/22/15 / #20150297790

Hyaluronic acid-based gels including lidocaine

Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. ... Allergan Inc

10/22/15 / #20150297492

Dry dermal filler compositions and methods of reconstitution

Dermal fillers are provided, particularly hyaluronic acid-based dermal fillers containing additives, for example, unstable additives, the dermal fillers being provided in an anhydrous state for extended shelf life.. . ... Allergan Inc

10/01/15 / #20150272948

Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists

. . The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. ... Allergan Inc

10/01/15 / #20150272898

Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods

Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. ... Allergan Inc

10/01/15 / #20150272877

Ketorolac-containing sustained release drug delivery systems

Biodegradable intraocular and intraarticular drug delivery systems comprising ketorolac and a biodegradable polymer matrix that can release ketorolac into an eye or joint for an extended period of time are described. The drug delivery systems may be in the form of an extruded implant and may be used to treat one or more medical and ocular conditions, such as post-operative pain and inflammation following an ocular surgery such as cataract surgery.. ... Allergan Inc

09/24/15 / #20150265633

Steroid containing drug delivery system

Pharmaceutical composition for intraocular use comprising a glucocorticoid derivative, such as beclomethasone 17,21-diproprionate admixed with a biodegradable polymer such as a poly(lactide-co-glycolide) polymer or a high molecular weight polymeric hyaluronic acid are disclosed.. . ... Allergan Inc

09/24/15 / #20150265573

Coumarin compounds as receptor modulators with therapeutic utility

The present invention relates to novel 2-oxo-2h-chromene-3-carboxamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. . ... Allergan Inc

09/17/15 / #20150258048

Therapeutic agents

The invention provides well-defined compounds that are either ep2 agonists, ep4 agonists, or mixed ep2/ep4 agonist. The compounds are useful for treating a variety of pathological conditions associated with activity of the ep2 and/or ep4 receptors.. ... Allergan Inc

09/17/15 / #20150257991

Melanin modification compositions and methods of use

A method for the modification of melanin distribution, and the composition thereof to modify melanin distribution are disclosed. A method for the reduction of melanin distribution, and the composition thereof to reduce melanin distribution are disclosed. ... Allergan Inc

09/10/15 / #20150250764

Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3himidazole derivatives for treating retinal diseases

The present invention relates to pharmaceutical compositions, containing 4-[1-(2,3-dimethylphenyl)ethyl]-1h-imidazole, (s) 4-[1-(2,3-dimethylphenyl)ethyl]-1h-imidazole or (s) [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, their use as pharmaceuticals for the treatment of retinal diseases, for retinal neuroprotection and vision enhancement.. . ... Allergan Inc

08/27/15 / #20150239987

Complement factor bb antibodies

The present disclosure relates to antibodies and polynucleotides encoding the same, which may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement factor bb. ... Allergan Inc

08/27/15 / #20150238698

Aspiration syringe accessory

A device is provided for facilitating an aspiration procedure during a dermal filler injection treatment. The device can be connected to a dermal filler syringe plunger, and includes a thumb stop element for engaging a physician's thumb.. ... Allergan Inc

08/27/15 / #20150238687

Intraocular implant delivery apparatus and methods of use thereof

Apparatus and methods for introducing a solid or semi-solid intraocular drug-containing implant into the anterior chamber of an eye are described. The drug-containing implant can be a rod-shaped biodegradable implant that may provide for the extended release of the drug and may be effective for treating a medical condition of the eye. ... Allergan Inc

08/20/15 / #20150232905

Methods of activating clostridial toxins

The specification discloses modified clostridial toxins comprising an exogenous clostridial toxin di-chain loop protease cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified clostridial toxins; method of producing such modified clostridial toxins, method of activating such modified clostridial toxins and methods of activating recombinantly-expressed clostridial toxins.. . ... Allergan Inc

08/20/15 / #20150231158

Novel oxime derivatives as sphingosine 1-phosphate (s1p) receptor modulators

The present invention relates to novel oxime derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. . ... Allergan Inc

08/20/15 / #20150231140

Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds

Disclosed herein are methods of treating a patient suffering from a cognitive disorder using the following compounds:. . ... Allergan Inc

08/20/15 / #20150231128

Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

The present invention relates to a method for treating skin diseases and skin conditions in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically acceptable salt thereof.. . ... Allergan Inc

08/13/15 / #20150224119

Implants and methods for treating inflammation-mediated conditions of the eye

Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μg/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μg/ml dexamethasone for at least about three weeks.. . ... Allergan Inc

08/13/15 / #20150224115

Preservative free bimatoprost and timolol solutions

The present invention is directed to preservative-free solutions of bimatoprost and timolol for lowering intra-ocular pressure and treatment of glaucoma.. . ... Allergan Inc

08/13/15 / #20150224080

Methods of treating alpha adrenergic mediated conditions

Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an α-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.. ... Allergan Inc

08/06/15 / #20150218119

Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators

The present invention relates to novel benzofuran-2-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.. . ... Allergan Inc

08/06/15 / #20150216953

Botulinum toxin therapy for skin disorders

Methods for treating skin disorders by local administration of a clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder.. . ... Allergan Inc

07/30/15 / #20150210689

Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation

Compounds, processes for their preparation, pharmaceutical compositions containing such compounds and their use in treating therapeutic conditions, in particular conditions mediated by the action of ligands on the fp, dp, ep1, ep4, ip, dp1, fp and tp prostaglandin (pg) receptors thereby providing a general anti-inflammatory response.. . ... Allergan Inc

07/30/15 / #20150209523

Substance delivery device

A substance delivery device that includes a hypodermic needle with a tube for receiving and containing a volume of a substance. The substance delivery device includes a rod, a portion of which is of a size and shape to fit within the tube of the hypodermic needle. ... Allergan Inc

07/30/15 / #20150209351

Alpha adrenergic receptor modulators

Compounds are described herein useful for treating diseases and conditions by modulation of one or more alpha adrenergic receptor. The compounds can include a naphthalene, a quinoline, a benzoimidazole or an isoquinoline as a core structure. ... Allergan Inc

07/30/15 / #20150209343

Topical dermal compositions

The present invention provides topical dermal compositions useful for treating a variety of conditions associated with excess sebum production, such as for example acne.. . ... Allergan Inc

07/30/15 / #20150209342

Topical retinoid formulations, processes for making and methods of use

The present invention provides topical dermal compositions including the compositions of the invention are useful for treating a variety of conditions associated with excess sebum production, such as, for example, acne.. . ... Allergan Inc

07/30/15 / #20150209276

Extended release biodegradable ocular implants

Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.. ... Allergan Inc

07/30/15 / #20150209265

Spherical forms of cross-linked hyaluronic acid and methods of use thereof

This disclosure relates generally to spherical forms comprising cross-linked hyaluronic acid, methods of making such spherical forms and using thereof, for example, in aesthetic applications (e.g., facial contouring, soft tissue augmentation products) and the like.. . ... Allergan Inc

07/30/15 / #20150209177

Container closure system with integral antimicrobial additives

A container-closure system includes a sterile vessel configured to store a preservative-free therapeutic agent. A polymeric applicator is fluidly coupled to the vessel through which the therapeutic agent is dispensed. ... Allergan Inc

07/16/15 / #20150197739

Fusion proteins and methods for treating, preventing or ameliorationg pain

A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, which protease is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a galanin targeting moiety that is capable of binding to a binding site on the nociceptive sensory afferent, which binding site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease and the galanin targeting moiety; a translocation domain that is capable of translocating the protease from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent; a first spacer located between the non-cytotoxic protease and the protease cleavage site, wherein said first spacer comprises an amino acid sequence of from 4 to 25 amino acid residues; and a second spacer located between the galanin targeting moiety and the translocation domain, wherein said second spacer comprises an amino acid sequence of from 4 to 35 amino acid residues. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.. ... Allergan Inc

07/16/15 / #20150196684

Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation

Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent. ... Allergan Inc

07/16/15 / #20150196582

Compositions for the treatment of dry eye

The present invention relates to ophthalmic compositions and methods useful to treat dry eye, or to diagnose, cure, mitigate, treat, or prevent dry eye syndrome in man or other animals.. . ... Allergan Inc

07/02/15 / #20150184141

Process and system for obtaining botulinum neurotoxin

Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.. . ... Allergan Inc

06/25/15 / #20150175586

Therapeutic agents for ocular hypertension

This invention provides well defined 6-alkyl or hydroxyalkyl-1-naphthamide or quinoline compounds for treating glaucoma or ocular hypertension.. . ... Allergan Inc

06/25/15 / #20150175567

Secondary amines as therapeutic agents

Compounds such as those represented by formulas 1-6 can be used in topical liquids, creams, or other dosage forms such as solids, for reducing intraocular pressure, treating glaucoma, growing hair, or other medical uses.. . ... Allergan Inc

06/25/15 / #20150174292

Thermoresponsive compositions for dermatological use and methods thereof

The present specification generally relates to compositions comprising a thermoresponsive polymer and methods of treating a soft tissue condition using such compositions.. . ... Allergan Inc

06/25/15 / #20150174095

Pharmaceutical compositions for the treatment of visual system disorders

The present invention relates to pharmaceutical compositions comprising d-serine transporter inhibitors which are proline analogues and therapeutic methods using such pharmaceutical compositions in methods for the treatment of visual system disorders and the enhancement of the visual function.. . ... Allergan Inc

06/25/15 / #20150174062

Biodegradable drug delivery system

A drug delivery system (dds) comprised of segmented biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The segmented implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer, and permit the dds to have segments that possess individual and different drug release characteristics.. ... Allergan Inc

06/18/15 / #20150166597

Polymorphic forms of a steroid-like compound and methods for the preparation and use thereof

Provided herein are multiple solid forms of a defined steroid-like compound, and methods for the preparation and use thereof. In one aspect, there is provided a crystalline form of said steroid-like compound, and methods for the preparation and use thereof. ... Allergan Inc

06/18/15 / #20150166521

Substituted dialkyl(oxido)-lambda4-sulfanylidene nicotinamide derivatives as kinase inhibitors

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.. . ... Allergan Inc

06/18/15 / #20150166518

Substituted nicotinamide derivatives as kinase inhibitors

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.. . ... Allergan Inc

06/18/15 / #20150166504

Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof

Provided herein are multiple solid forms of a defined α,{acute over (ω)}-disubstituted dihydroxy cyclopentyl compound, and methods for the preparation and use thereof. In one aspect, there are provided crystalline forms of said cyclopentyl compound, and methods for the preparation and use thereof. ... Allergan Inc

06/18/15 / #20150165050

Cyclosporin compositions

A composition comprising from about 0.001% to about 0.4% cyclosporin a, a surfactant, and an oil having a specific gravity from 0.8 to 0.95 is disclosed herein.. . ... Allergan Inc

06/18/15 / #20150164982

Cyclosporin compositions

A composition comprising a therapeutically effective amount of cyclosporin a, a blend of oils having a specific gravity of from 0.90 to 1.07, and a surfactant is disclosed herein.. . ... Allergan Inc

06/18/15 / #20150164863

Compositions for delivery of therapeutics into the eyes and methods for making and using same

The present invention provides for compositions for administering a therapeutically effective amount of a therapeutic component. The compositions may include an ophthalmically acceptable carrier component; a therapeutically effective amount of a therapeutic component; and a retention component which may be effective to reduce wettability, induce viscosity, increase muco-adhesion, increase meniscus height on a cornea of an eye and/or increase physical apposition to a cornea of an eye of a composition.. ... Allergan Inc

06/11/15 / #20150157568

Treatment of spasticity with intrathecal dantrolene

. . The present invention is directed to a method of treating spasticity in a human subject, comprising administering intrathecally to the subject a therapeutically effective amount of dantrolene or a pharmaceutically acceptable salt thereof. The administration can be through a chronical drug delivery device such as an intrathecal pump.. ... Allergan Inc

06/04/15 / #20150152080

Benzothiophene sulfonamides derivatives as chemokine receptor modulators

The present invention relates to benzothiophene sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.. . ... Allergan Inc

06/04/15 / #20150151052

Syringe

A syringe is disclosed. The syringe may include a syringe body with a fluid chamber, the syringe body having a distal end and a proximal end, with an extrusion opening at the proximal end; a dividing wall disposed within the fluid chamber, defining a first fluid chamber and a second fluid chamber, the first fluid chamber and the second fluid chamber in communication with the extrusion opening; a first plunger disposed in a distal end of the first chamber, the first plunger including a first locking mechanism configured to prevent the first plunger from sliding away from the proximal end of the syringe body, when the first plunger is in a first initial position and the second plunger is being depressed; and a second plunger disposed in a distal end of the second chamber, the second plunger including a second locking mechanism configured to prevent the second plunger from sliding away from the proximal end of the syringe body when the second plunger is in a second initial position and the first plunger is being depressed.. ... Allergan Inc

06/04/15 / #20150150880

Hypotensive lipid and timolol compositions and methods of using same

New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. ... Allergan Inc

05/28/15 / #20150148823

Pliable silk medical device

An implantable, pliable knitted silk mesh for use in human soft tissue support and repair having a particular knit pattern that substantially prevents unraveling and preserves the stability of the mesh when cut, the knitted mesh including at least two yarns laid in a knit direction and engaging each other to define a plurality of nodes.. . ... Allergan Inc

05/28/15 / #20150148395

Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators

The present invention relates to novel amide derivatives of n-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the n-formyl peptide receptor like-1 (fprl-1) receptor.. . ... Allergan Inc

05/28/15 / #20150148394

Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions

The present invention relates to method for treating skin diseases and skin conditions in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, or enantiomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.. . ... Allergan Inc

05/28/15 / #20150147406

Intraocular formulation

Biodegradable therapeutic agent incorporating microspheres formulated in a high viscosity carrier suitable for intraocular administration to treat an ocular condition. The formulation can also be used to treat non-ocular conditions such as articular pathologies. ... Allergan Inc

05/21/15 / #20150141484

Methods, compositions and drug delivery systems for intraocular delivery of sirna molecules

Biocompatible intraocular drug delivery systems in the form of an implant for intraocular administration of sirna molecules. The drug delivery systems may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.. ... Allergan Inc

05/21/15 / #20150141348

Sustained release sirna for ocular drug delivery

The present invention provides an ocular implant comprising sirna complexed with a transfection agent selected from the group consisting of cationic lipids and short cell penetration peptides, wherein said complex is associated with a biocompatible polymer. Said biocompatible polymer comprises a polymeric matrix configured to release said complex into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease.. ... Allergan Inc

05/21/15 / #20150140062

Methods of treatment of ocular conditions with a sustained drug delivery implant

Intraocular implants may include a corticosteroid and a biodegradable polymer associated with the corticosteroid to facilitate the release of the corticosteroid into an eye for a period of time. In some embodiments, ocular conditions, such as diabetic macular edema can be treated through administration of an intraocular implant including a corticosteroid and a biodegradable polymer associated with the corticosteroid to the eye of a human at a frequency of about once every six months to about once a year.. ... Allergan Inc

05/07/15 / #20150126929

Dermal filler injector

A dermal filler injector is provided which includes a handpiece and a coupling mechanism for operationally coupling the handpiece with a dermal filler cartridge. The handpiece includes a motor for controllably driving a plunger in the cartridge to provide effective and controlled injection of a dermal filler into skin.. ... Allergan Inc

05/07/15 / #20150126458

Method of treating conditions of the eye with an anti-vegf darpin

Disclosed herein are methods for the treatment of a patient having an exudative age-related macular degeneration and other conditions of the retina by administering a binding protein comprising an ankyrin repeat domain, wherein the binding protein is first administered in 2 to 5 doses, with an interval of 25 to 35 days between each dose, and then is administered in additional doses with a longer interval between doses.. . ... Allergan Inc

04/30/15 / #20150119467

Methods for treatment of pelvic pain and/or comorbid conditions

Methods, systems, devices, and medicaments are provided for locally administering to a pelvic-area organ or tissue structure in a patient at least one drug continuously or continually over a treatment period of 24 hours or more in an amount effective to achieve a therapeutic effect in another organ or tissue structure by means of shared or convergent pelvic afferent pathways. The methods systems, devices, and medicaments can be used in the treatment of ic/bps, chronic pelvic pain, vulvodynia, orchialgia, urethral syndrome, dysparenia, chronic prostatitis, chronic pelvic pain, levator ani syndrome, irritative bowel syndrome, or a combination thereof. ... Allergan Inc

04/30/15 / #20150119454

Therapeutic cyclopentanols, compositions thereof, and methods for use thereof

Described herein are well-defined cyclopentanols useful for treating glaucoma and ocular hypertension.. . ... Allergan Inc

04/30/15 / #20150119438

3-propanoic acid in crystalline form and methods for use thereof

The present invention provides 3-{1-[5-chloro-2-(2-ethylbutoxy)benzyl]-5-methyl-1h-pyrazol-3-yl}propanoicacid in crystalline form. The present invention further provides methods for treating disorders associated with dp1, fp, tp, ep1 and ep4 prostaglandin (pg) receptors.. ... Allergan Inc

04/30/15 / #20150119367

Phosphate esters of bimatoprost and the prostamides

Provided herein, inter alia, are prodrugs of bimatoprost, methods of using the same and compositions including the same.. . ... Allergan Inc

04/30/15 / #20150118279

Prostamide-containing intraocular implants and methods of use thereof

Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. ... Allergan Inc

04/16/15 / #20150104514

Implantable silk-based tissue prostheses

A silk fiber based matrix composition comprising spider silk that can be biodegradable, from the spider species nephila clavipes (or from genetically engineered bacteria making nephila clavipes silk), and in the form of a mesh or film.. . ... Allergan Inc

04/16/15 / #20150104491

Sustained-release reservoir implants for intracameral drug delivery

The present invention provides a sustained release implant for intraocular use to treat elevated intraocular pressure, which implant is configured for intracameral or anterior vitreal administration to a patient with elevated intraocular pressure (iop), said implant comprising a core of an antihypertensive agent surrounded by a polymer, which limits the rate of passage of the antihypertensive agent from the implant into the eye of said patient and said implant provides a linear rate of release of therapeutically effective amounts of said anti-hypertensive agent into the eye for a period of time of between 14 days and 365 days.. . ... Allergan Inc

04/09/15 / #20150099807

Preservative free bimatoprost solutions

The present invention is directed to preservative-free solutions of bimatoprost for lowering intraocular pressure and treatment of glaucoma.. . ... Allergan Inc

04/09/15 / #20150099805

Hypotensive lipid-containing biodegradable intraocular implants and related methods

Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. ... Allergan Inc

04/09/15 / #20150099755

Novel fluoroergoline analogs

Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. ... Allergan Inc

04/09/15 / #20150099746

Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.. . ... Allergan Inc

04/02/15 / #20150094330

Compounds and methods for skin repair

The invention provides compositions and methods for wound healing and scar reduction. The compositions and methods of the invention include at least one ep4 agonist set forth herein. ... Allergan Inc

03/26/15 / #20150087696

Method of controlling initial drug release of sirna from sustained-release implants

. . The present invention provides an intraocular implant comprising sirna combined with a excipient effective to retard the initial release of the sirna from an implant, wherein said sirna and excipient is associated with a biocompatible polymer (e.g., a polymeric matrix), configured to release said sirna into the eye of a patient at therapeutic levels for a time sufficient to treat an ocular condition or disease.. . ... Allergan Inc

03/26/15 / #20150087647

Combination of brimonidine and timolol for topical ophthalmic use

Disclosed are pharmaceutical compositions comprising brimonidine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.. . ... Allergan Inc

03/26/15 / #20150086531

Methods for modifying progression of osteoarthritis

Methods for modifying progression of osteoarthritis by local administration of a clostridial derivative, such as a botulinum toxin, to an arthritis-affected site are disclosed herein.. . ... Allergan Inc

03/19/15 / #20150080845

Polymer system for securing implants in syringe needles

. . Disclosed herein are methods of delivering implants to a target organ with an implant administration device, where the implant administration device includes a polymer retainer. Methods of making polymer retainers and methods of securing an implant within an implant administration device using a polymer retainer are also disclosed herein.. ... Allergan Inc

03/19/15 / #20150080466

Diphenyl urea derivatives as formyl peptide receptor modulators

The present invention relates to diphenyl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the n-formyl peptide receptor 2.. . ... Allergan Inc

03/19/15 / #20150080445

Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol

Disclosed herein is a pharmaceutical composition comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol and methods of using the composition to treat chronic pain.. . ... Allergan Inc

03/05/15 / #20150065701

Injectable monophase hydrogels

An injectable monophase hydrogel is provided and is made of a reaction mixture of a high molecular weight hyaluronic acid and a low molecular weight hyaluronic acid.. . ... Allergan Inc

03/05/15 / #20150065433

Cyclosporin analogs

Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.. . ... Allergan Inc

03/05/15 / #20150064167

Method for treating premature ejaculation with a botulinum neurotoxin

Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a clostridial neurotoxin, such a botulinum neurotoxin, to the patient, are provided.. . ... Allergan Inc

03/05/15 / #20150064165

Devices and methods for reducing the appearance of cellulite

Methods and devices for use in reducing the appearance of dimpled skin or other undesirable appearance of skin in a cellulitic region of a patient are provided. The methods include the steps of disrupting fibrous septae located beneath the skin of a cellulitic region and introducing a composition beneath the skin, the composition being effective to reduce or prevent regrowth of the fibrous septae.. ... Allergan Inc

03/05/15 / #20150064147

Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation

Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a collagen component.. ... Allergan Inc

02/26/15 / #20150057685

Medical device with anti adhesive property

Laminate or knitted medical devices and methods using such devices to support soft tissues and/or to reduce formation of post-operative adhesions. The medical devices can comprise a layer of a knitted silk mesh to which has been fused a water soluble or insoluble silk film or silk sponge, and/or a layer of a knitted silk mesh which was co-knitted with one, two or three layers of silk or non-silk fabric.. ... Allergan Inc

02/26/15 / #20150057381

Porogen compositions, methods of making and uses

Provided are porogen compositions and methods of using such porogen compositions in the manufacture of porous materials, for example, porous silicone elastomers. The porogens generally include comprising a core material and shell material different from the core material. ... Allergan Inc

02/26/15 / #20150057327

Ketorolac tromethamine compositions for treating or preventing ocular pain

Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.. ... Allergan Inc

02/26/15 / #20150057261

Azetidine derivatives as sphingosine-1 phosphate receptors modulators

The present invention relates to azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. . ... Allergan Inc

02/26/15 / #20150057258

4-pregenen-11beta-17-21-triol-3,20-dione derivatives

The present invention relates to novel 4-pregenen-11β-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.. ... Allergan Inc

02/26/15 / #20150057253

Alkyl derivatives as sphingosine-1 phosphate receptors modulators

The present invention relates to alkyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. . ... Allergan Inc

02/26/15 / #20150056261

Silk medical devices

Laminate medical devices and methods using such devices to support soft tissues and/or to reduce formation of post-operative adhesions. The medical devices can comprise a layer of a knitted silk mesh to which has been fused a water soluble silk film.. ... Allergan Inc

02/19/15 / #20150051253

( ) (2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (l)-(+) tartrate salt, its method of production and use

The present invention is directed to (−)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (l)-(+)tartrate salt, a pharmaceutical composition comprising said salt, a process for making said salt, and the use of said salt in the treatment of pain.. . ... Allergan Inc

02/19/15 / #20150051186

Aryl azetidine derivatives as sphingosine-1 phosphate receptors modulators

The present invention relates to aryl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. . ... Allergan Inc

02/19/15 / #20150051176

Aryl derivatives as sphingosine-1 phosphate receptors modulators

The present invention relates to aryl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. . ... Allergan Inc

02/12/15 / #20150045403

Pharmaceutical cream compositions and methods of use

Embodiments relating to cream formulations as well as oxymetazoline creams and methods for treating rosacea and symptoms associated with rosacea, including, for example, papules, pustules, phymas (skin thickening), telangiectasias or erythema associated with rosacea, other skin erythemas, telangiectasias, purpura or the like, and other manifestations associated therewith; other inflammatory conditions of the skin including, but not limited to, keratosis pilaris, lupus miliaris dissemniatus faciei, eczema, dermatitis, such as contact dermatitis, atopic dermatitis, seborrheic dermatitis, nummular dermatitis, generalized exfoliative dermatitis, statis dermatitis, neurodermatitis, lichen simplex chronicus, xerosis and xerotic dermatitis, dyshidrosis and dyshidrotic dermatitis, asteototic dermatitis or other conditions characterized by sensitive skin or a disturbance of the epidermal barrier; disorders characterized by rough, dry, cracked or fissured skin, disorders characterized by hyperkeratotic skin such as keratodermas and ichthyosisis and ichthyosiform dermatoses; disorders of hair follicles and sebaceous glands, such as acne, perioral dermatitis, and pseudofolliculitis barbae; disorders of sweat glands, such as miliaria, including, but not limited to, miliaria crystallina, miliaria rubra, miliaria profunda, miliaria pustulosa; sunburn, chronic actinic damage, poikiloderma, radiation dermatitis, actinic purpura (“solar purpura”); other inflammatory dermatoses, reactions and conditions of the skin, including, but not limited to, psoriasis, drug eruptions, erythema multiforme, erythema nodosum, and granuloma annulare; diseases and conditions characterized by bleeding or bruising such as petechiae, ecchymosis, purpura and the like including any accumulation of blood in the skin due to vascular extravasation, irrespective of size or cause, bleeding or bruising due to any skin injury which may include any trauma including surgical or procedural trauma; infection, inflammatory dermatoses or inflammation due to any cause using such creams are described herein.. . ... Allergan Inc

02/12/15 / #20150045341

Disubstituted aryl azetidine derivatives as sphingosine-1 phosphate receptors modulators

The present invention relates to disubstituted aryl azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. . ... Allergan Inc

02/12/15 / #20150045328

Disubstituted aryl oxy derivatives as sphingosine-1 phosphate receptors modulators

The present invention relates to aryl oxy derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. . ... Allergan Inc

02/12/15 / #20150045321

Hyaluronic acid based formulations

Disclosed herein are soft tissue fillers, for example, dermal and subdermal fillers, based on low molecular weight hyaluronic acids and pharmaceutically acceptable salts thereof, and methods of manufacturing same.. . ... Allergan Inc

02/12/15 / #20150045309

Cyclosporin emulsions

Disclosed herein is a composition comprising cyclosporin a at a concentration between about 0.001% (w/v) and about 1.0% (w/v), a plant oil at a concentration between about 0.01% (w/v) and about 10% (w/v), and macrogol 15 hydroxystearate at a concentration between about 0.01% (w/v) and about 10% (w/v).. . ... Allergan Inc

02/05/15 / #20150038918

Slotted syringe

A syringe is disclosed. The syringe may include a syringe body, a first slot formed in the syringe body, a first sleeve covering the first slot, a thumb grip including a first slot guide disposed in the first slot, the thumb grip shaped to slide from a first position near the distal end of the syringe body toward a second position near the proximal end of the syringe body, and a plunger disposed in the fluid chamber of the syringe body. ... Allergan Inc

02/05/15 / #20150038456

Stable hydrogel compositions including additives

The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions.. . ... Allergan Inc

01/29/15 / #20150031614

Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor

The invention provides methods and compositions for use of desmopressin in combination with a 5-alpha reductase inhibitor. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.. ... Allergan Inc

01/29/15 / #20150031613

Methods and compositions comprising desmopressin in combination wtih a beta-3-adrenergic receptor agonist

The invention provides methods and compositions for use of desmopressin in combination with a beta-3-adrenergic receptor agonist. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.. ... Allergan Inc

01/29/15 / #20150028510

Porous materials, methods of making and uses

The present specification discloses porous materials, methods of forming such porous materials, materials and devices comprising such porous materials, and methods of making such materials and devices.. . ... Allergan Inc

01/22/15 / #20150025459

Multi-site injection system

A multi-site injection system includes a plurality of medicament delivering needles/microprotrusions, a needle/microprotrusion support, a supply of medicament, and a mechanism for providing the medicament to the plurality of needles/microprotrusions in order to effect delivery into a stratum corneum of a user.. . ... Allergan Inc

01/22/15 / #20150025062

Hcn inhibitors affecting ganglion cell function and visual function

The present invention is directed to a method of enhancing visual function in a subject, comprising administering to the subject in need of such enhancement, a therapeutically effective amount of an inhibitor of a hyperpolarization-activated cyclic nucleotide-gated (hcn) channel. The present invention is also directed to an ocular implant comprising a therapeutically effective amount of the hcn channel inhibitor.. ... Allergan Inc

01/22/15 / #20150025061

Gabaa receptor antagonists affecting ganglion cell function and visual acuity

The present invention is directed to a method of enhancing visual acuity in a subject, comprising intravitreally administering to the subject in need of such enhancement, a therapeutically effective amount of an extrasynaptic gabaa receptor antagonist. The present invention is also directed to an ocular implant comprising a therapeutically effective amount of the extrasynaptic gabaa receptor antagonist.. ... Allergan Inc

01/22/15 / #20150025021

Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators

The present invention relates to derivatives of n-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the n-formyl peptide 2 receptor.. . ... Allergan Inc

01/15/15 / #20150018358

Compositions and methods for treating purpura

. . Embodiments of the present invention are directed to compositions and methods for the treatment of purpura. Preferred compositions comprise an α adrenergic receptor agonist selected from selective α1 adrenergic receptor agonist, selective α2 adrenergic receptor agonist, non-selective α1/α2 adrenergic receptor agonist, agents with α2 adrenergic receptor agonist activity and combinations thereof, in a pharmaceutically acceptable carrier in order to treat and improve the cosmetic appearance of hemorrhagic (purpuric) lesions in the skin.. ... Allergan Inc

01/15/15 / #20150018310

Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.. . ... Allergan Inc

01/08/15 / #20150011480

Method of treating blurred vision and other conditions of the eye with cyclosporin compositions

. . Disclosed herein is a method of treating blurred vision, of increasing keratocyte density, of increasing goblet cell density, and of treating psychological distress following surgery on the eye, the method comprising administering a cyclosporin composition to the affected eye of an individual.. . ... Allergan Inc

01/08/15 / #20150010533

Botulinum toxin therapy for skin disorders

Methods for treating skin disorders by local administration of a clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder.. . ... Allergan Inc

01/01/15 / #20150005519

Pharmaceutical compositions and methods of use of 4-pregenen-11beta-17-21-triol-3,20-dione derivatives

The present invention relates to pharmaceutical compositions comprising 4-pregenen-11β-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (gr) and/or the mineralocorticoid receptors (mr). The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors (gr) and/or the mineralocorticoid receptors (mr).. ... Allergan Inc

01/01/15 / #20150005377

Ester derivatives of bimatoprost compositions and methods

Provided herein, inter alia, are prodrugs of bimatoprost, methods of using the same and compositions including the same.. . ... Allergan Inc

01/01/15 / #20150005312

Compositions containing alpha-2-adrenergic agonist components

Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. ... Allergan Inc

01/01/15 / #20150005272

Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor

Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.. . ... Allergan Inc

01/01/15 / #20150004243

Oil-in-water method for making polymeric implants containing a hypotensive lipid

Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. ... Allergan Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Allergan Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Allergan Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###